Jan 16 BioGen

Notizia

UK based company conducting clinical trials on World’s First Universal Flu Vaccine

UK based company Vaccitech is currently conducting a clinical trial on a prospective drug that could serve as a universal flu vaccine in the world. Currently, there is no vaccine in the market that can be used for multiple flu problems. The company has got the patent for the vaccine MVA-NP+M1 and so far has been successfully tested for safety across 145 people.

First ever treatment for breast cancer with a certain inherited genetic mutation approved by USFDA

USFDA has recently approved Lynparza (olaparib tablets) for the treatment of patients with certain types of breast cancer that have metastasized and tumors having a specific inherited genetic mutation. It is by far the only drug in its class (PARP inhibitor) approved for the treatment of breast cancer, and also the first one to treat certain patients with metastatic breast cancer having “BRCA” gene mutation.

Immunology player KWS BioTest bought by Charles River for USD 20 million

Immunology player British CRO KWS BioTest is now a part of Charles River Laboratories after a deal worth USD 20 million, boosting the portfolio of Charles River in different therapeutic areas namely immuno-oncology and inflammatory and infectious diseases. KWS Biotest specializes in offering in vitro and in vivo testing services in immunology.

Forty Seven added Roche as a second partner for developing CD47 cancer immunotherapy

Forty Seven has recently added Roche as a second partner for its CD47-targeted immuno-oncology drug candidate, Roche’s Genentech unit has agreed to sponsor two trials of the antibody in combination with its PD-L1 inhibitor Tecentriq. This is a second partnership signed for the lead drug Hu5F9-G4 after getting Merck KGaA onboard last November to test the drug in combination with the recently approved Bavencio in a Phase 1b ovarian cancer trial.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.